Navigation Links
Cardinal Health Updates FY09 Outlook
Date:1/8/2009

DUBLIN, Ohio, Jan. 8 /PRNewswire-FirstCall/ -- Cardinal Health today announced it expects to report solid earnings per share (EPS) results for its fiscal second quarter, but provided caution for the remainder of the fiscal year because of a deferral in hospital capital spending affecting its Clinical and Medical Products segment.

Non-GAAP diluted EPS from continuing operations(1) for the company's fiscal second quarter, ended Dec. 31, 2008, is anticipated to be at least $0.90, driven by solid operating results and a better than expected tax rate. In addition, the company reaffirmed its previously announced full-year revenue and segment profit goals for its Healthcare Supply Chain Services segment, but is updating its EPS guidance for the full year.

"It is difficult to forecast the exact duration and potential long-term changes in hospital spending patterns, but the company is taking appropriate cost actions to mitigate the impact," said R. Kerry Clark, chairman and CEO of Cardinal Health. "Based on our current data, we anticipate full-year non-GAAP EPS to be in a range of $3.50 to $3.60 versus a previously provided range of $3.80 to $3.95."

David Schlotterbeck, CEO of Clinical and Medical Products said, "With the delay in hospital capital spending, we expect softness in our capital equipment sales to continue in the second half of the fiscal year. It is important to note that more than 40 percent of our Clinical and Medical Products business comes from the sale of disposable products and remains stable. There are also segments of our capital equipment business less affected, and therefore we expect Clinical and Medical Products segment results for the fiscal year to be flat or better than last fiscal year."

George Barrett, CEO of Healthcare Supply Chain Services said, "Our team has made considerable progress over the past nine months, and in spite of an extraordinary economic c
'/>"/>

SOURCE Cardinal Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
2. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
3. Cardinal Health To Announce First-Quarter Results on November 5
4. Cardinal Health Announces Sector Management Change
5. Cardinal Health Reports First Quarter Results
6. Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved
7. Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility
8. Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHIS 5 Million Lives Campaign
9. Cardinal Health to Cease Distribution of Controlled Substances from Florida Facility
10. Cardinal Health to Announce Second-Quarter Results on January 29
11. Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Cephalon Quarterly Conference Call Invitation 12853 1Police work undermines cardiovascular health comparison to general population shows 50430 1Police work undermines cardiovascular health comparison to general population shows 50430 2Police work undermines cardiovascular health comparison to general population shows 50430 3Bladder Cancer No Longer a Death Sentence 50427 1Bladder Cancer No Longer a Death Sentence 50427 2Bladder Cancer No Longer a Death Sentence 50427 3